Evidence map›Paper›PMID 36345848›Full record

ArticleMolecular oncology2023

MicroRNA signature of small-cell lung cancer after treatment failure: impact on oncogenic targets by miR-30a-3p control.

Kengo Tanigawa, Shunsuke Misono, Keiko Mizuno, Shunichi Asai, Takayuki Suetsugu, Akifumi Uchida, Minami Kawano, Hiromasa Inoue, Naohiko Seki

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. The microRNA Expression Signature of Lung Adenocarcinoma HarboringInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. miR-30a-3p Regulates Autophagy in the Involution of Mice Mammary Glands.International journal of molecular sciences · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kengo TanigawaDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.ORCID 0000-0002-6785-8808
Shunsuke MisonoDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Keiko MizunoDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Shunichi AsaiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Japan.
Takayuki SuetsuguDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Akifumi UchidaDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Minami KawanoDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Hiromasa InoueDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
Naohiko SekiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Japan.ORCID 0000-0003-4731-7956
Kagoshima University · JPChiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small-cell lung cancer (SCLC) is associated with a high mortality rate and limited treatment efficacy. We created a microRNA (miRNA) expression signature by RNA sequencing using specimens from patients with SCLC who had failed treatment. Forty-nine miRNAs were downregulated in SCLC tissues and were candidate tumor-suppressive miRNAs. In this signature, both guide and passenger strands were downregulated for five miRNAs (miR-30a, miR-34b, miR-34c, miR-223, and miR-4529). Recent studies have revealed that passenger strands of miRNAs are involved in the molecular pathogenesis of human cancer. Although miR-30a-5p (the guide strand) has been shown to be a tumor-suppressive miRNA in various types of cancers, miR-30a-3p (the passenger strand) function is not well characterized in SCLC cells. We investigated the functional significance of miR-30a-3p and oncogenic genes regulated by miR-30a-3p in SCLC cells. Ectopic expression assays showed that miR-30a-3p expression inhibited cell proliferation and induced cell cycle arrest and apoptosis in two SCLC cell lines. Furthermore, in silico database searches and gene expression assays identified 25 genes as putative targets of miR-30a-3p in SCLC cells. Luciferase reporter assays revealed that downstream neighbor of SON (DONSON) was directly regulated by miR-30a-3p in SCLC cells. Knockdown of DONSON induced cell cycle arrest in SCLC cells and DONSON overexpression were detected in SCLC clinical samples. Analyzing the regulatory networks of tumor-suppressive miRNAs may lead to the identification of therapeutic targets in SCLC.

Indexed as

Lung NeoplasmsMicroRNAsSmall Cell Lung CarcinomaCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansTreatment FailureMicroRNAsdownstream neighbor of SONmicroRNA signaturemiR-30a-3psmall-cell lung cancertreatment failure

Identifiers

PMID36345848
PMCPMC9892828
OpenAlexW4308549236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.